Lexaria Bioscience Corp. (LEXX)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 2.6300 |
| Open | 2.6500 |
| Bid | 2.7100 x 100 |
| Ask | 2.8300 x 100 |
| Day's range | 2.5779 - 2.8297 |
| 52-week range | 0.7050 - 6.8500 |
| Volume | |
| Avg. volume | 231,944 |
| Market cap | 39.818M |
| Beta (5Y monthly) | 1.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6700 |
| Earnings date | 12 Jul 2024 - 16 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.00 |
Simply Wall St.Here's Why We're Watching Lexaria Bioscience's (NASDAQ:LEXX) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, Lexaria Bioscience...
- Simply Wall St.
This Lexaria Bioscience Insider Increased Their Holding By 23% Last Year
Insiders were net buyers of Lexaria Bioscience Corp.'s ( NASDAQ:LEXX ) stock during the past year. That is, insiders...
GlobeNewswireLexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/e7Vus With each new study, the horizon of GLP-1’s therapeutic potential expands, painting a vibrant picture of a future where a single molecu
© 2024 Yahoo. All rights reserved.